What blood work is necessary to diagnose an insulinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Blood Work for Insulinoma Diagnosis

The essential blood work for diagnosing insulinoma requires measuring insulin, C-peptide, and proinsulin levels during a supervised 48-72 hour fast when blood glucose drops below 55 mg/dL, with diagnostic thresholds of insulin >3 mcIU/mL, C-peptide ≥0.6 ng/mL, and proinsulin ≥5 pmol/L. 1

Supervised Fast Protocol

The supervised fast remains the gold standard diagnostic test for insulinoma:

  • A 48-72 hour supervised fast should be performed until hypoglycemia occurs or the time limit is reached 1
  • The fast can be terminated when blood glucose falls below 55 mg/dL (some sources use 40-45 mg/dL) 1, 2
  • 94.5% of insulinomas will be diagnosed within 48 hours, making the 48-hour fast sufficient for most cases 2
  • Only 5.5% of patients require fasting beyond 48 hours 2

Critical Blood Tests at Fast Termination

When hypoglycemia is documented, the following must be measured simultaneously:

Insulin Level

  • Diagnostic threshold: >3 mcIU/mL (typically >6 mcIU/mL) 3, 1
  • Insulin >21 pmol/l (approximately 3 mcIU/mL) when glucose <45 mg/dL is diagnostic 4
  • Important caveat: Insulin alone has lower diagnostic accuracy than proinsulin and may be suppressed in some insulinoma cases 5

C-Peptide Level

  • Diagnostic threshold: ≥0.6 ng/mL 3, 1
  • C-peptide >0.2 nmol/L is present in all insulinomas 5
  • Critical function: Elevated C-peptide differentiates endogenous hyperinsulinemia (insulinoma) from exogenous insulin administration 1

Proinsulin Level

  • Diagnostic threshold: ≥5 pmol/L 3, 1
  • Proinsulin >5 pmol/L with glucose <45 mg/dL achieves 100% diagnostic specificity and sensitivity 5
  • Proinsulin is elevated at the beginning of the fast in 90% of insulinoma patients 2
  • Proinsulin is the most reliable single marker, as it can be elevated even when insulin and C-peptide are suppressed 6, 5

Additional Baseline Testing

Chromogranin A

  • May be measured as a general neuroendocrine tumor marker 3
  • Critical pitfall: Proton pump inhibitors cause spuriously elevated chromogranin A levels and must be discontinued at least 1 week before testing 3, 1
  • Other causes of false elevation include renal/liver failure, hypertension, and chronic gastritis 3

Algorithmic Approach to Blood Work

  1. Discontinue proton pump inhibitors at least 1 week before testing if chromogranin A will be measured 3

  2. Initiate supervised 48-72 hour fast with serial glucose monitoring 1

  3. At hypoglycemia (glucose <55 mg/dL), immediately draw:

    • Serum insulin
    • C-peptide
    • Proinsulin
    • Confirm glucose level 3, 1
  4. Diagnostic criteria met when ALL of the following are present:

    • Insulin >3 mcIU/mL
    • C-peptide ≥0.6 ng/mL
    • Proinsulin ≥5 pmol/L
    • Blood glucose <55 mg/dL 3, 1
  5. If proinsulin >5 pmol/L with glucose <45 mg/dL, diagnosis is confirmed with 100% accuracy 5

Common Diagnostic Pitfalls

  • Never rely on insulin levels alone, as 8-35% of insulinoma patients may have insulin <21 pmol/L during hypoglycemia 5
  • Proinsulin measurement is mandatory, not optional, as it may be the only elevated marker in some cases 6
  • Ensure all samples are drawn simultaneously at the time of documented hypoglycemia, not at arbitrary time points 1
  • Do not stop the fast prematurely—wait for clear neuroglycopenic symptoms or glucose threshold to be reached 2

References

Guideline

Diagnostic and Treatment Approach for Insulinoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Forty-eight-hour fast: the diagnostic test for insulinoma.

The Journal of clinical endocrinology and metabolism, 2000

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.